Objective: Using moderate or ultra-hypofractionation, which is also known as stereotactic
body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been …

Simple Summary Stereotactic body radiotherapy, ie, high-precision radiotherapy delivering
high doses within a few treatment sessions, is a very convenient treatment option, which has …

Purpose: To assess the optimal planning target volume (PTV) margins for stereotactic body
radiotherapy (SBRT) of prostate cancer based on inter-and intra-fractional prostate motion …

Following adoption of moderately hypofractionated radiotherapy as a standard for localised
prostate cancer, ultrahypofractioned radiotherapy delivered in five to seven fractions is …

Due to its low fractionation sensitivity, also known as “alpha/beta ratio,” in relation to its
surrounding organs at risk, prostate cancer is predestined for hypofractionated radiation …

Purpose This is the first report of the 2SMART Phase II trial evaluating the safety of two-
fraction stereotactic ablative radiotherapy (SABR) with focal boost to magnetic resonance …

Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the
disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after …

Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC
develops radio-resistance, highlighting a need for agents to improve radiotherapy response …

Background Normofractionated radiation regimes for definitive prostate cancer treatment
usually extend over 7–8 weeks. Recently, moderate hypofractionation with doses per …

Purpose Stereotactic magnetic resonance (MR)–guided adaptive radiation therapy (SMART)
for prostate cancer allows for MR-based contouring, real-time MR motion management, and …